Advanced NSCLC: new cytostatic agents.
There are several new cytostatic agents under investigation for the treatment of advanced non-small cell lung cancer either as first or second-line. In this review we will present the current information about oxaliplatin, epothilones, irinotecan and alimta.
Kosmidis
Paris A
PA
Medical Oncology Department, "Hygeia" Hospital, Athens Tsoha 2 street, Athens 11521, Greece. parkosmi@otenet.gr
Manegold
Christian
C
D000970:Antineoplastic Agents / Q000494:pharmacology*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D034261:Epothilones / Q000494:pharmacology*; D005971:Glutamates; D006147:Guanine / Q000031:analogs & derivatives*; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D000077150:Oxaliplatin; D000068437:Pemetrexed; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D034261:Epothilones; D005971:Glutamates; D009944:Organoplatinum Compounds; D000068437:Pemetrexed; D000077150:Oxaliplatin; D006147:Guanine; D000077146:Irinotecan; D013940:Thymidylate Synthase; D002166:Camptothecin